OneCell Diagnostics’ Mohan Uttarwar Discusses How AI Helps To Predict Cancer’s Next Move

Company Co-Founder Shares How Decoding Cancer At Single Cell Level Could Take Guesswork Out Of Recurrence With AI-Powered Diagnostics

Part 1 of 2: In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single cell biopsy platform is rewriting the rules of cancer diagnostics – not just identifying cancer at the cellular level but predicting its potential return with unprecedented accuracy. He also shares how the company’s approach leverages single cell biopsy technology and machine learning to spot signs of cancer’s return before it manifests clinically.

In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single-cell biopsy platform is rewriting the rules of cancer diagnostics
Key Takeaways

· OneCell's platform isolates and analyzes individual circulating tumor cells (CTCs) to provide a more granular and dynamic view of a patient's disease state.

· By training proprietary machine learning models on complex cell-level data, OneCell can assess recurrence risk — offering oncologists a powerful predictive tool for treatment planning.

· With early validation in motion and plans for wider clinical deployment, the company is focused on translating its technology into real-world oncology workflows.

In a world where cancer remains one of the most complex and relentless diseases, OneCell Diagnostics, an artificial intelligence-powered cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Interviews

More from Medtech Insight

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By 

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.

FTC Blocks Edwards Lifesciences’ Merger With JenaValve

 
• By 

The FTC is suing to block Edwards Lifesciences' purchase of JenaValve, citing concerns that it would reduce competition and innovation in the heart valve market and negatively impact patient access to vital treatments for aortic regurgitation. Edwards disagrees with the decision.

Swiss Medtech To Battle ‘Arbitrary’ 39% US Tariff

 
• By 

In return for building a successful US export business, Switzerland has been handed a 39% tariff effective immediately by the Trump administration. Diplomatic channels have been reopened to undo the tariff. Meanwhile, the medtech industry is looking to develop OUS markets for Swiss exporters.